118 related articles for article (PubMed ID: 10440870)
1. Molecular cytogenetic studies of a serially transplanted primary prostatic carcinoma xenograft (CWR22) and four relapsed tumors.
Kochera M; Depinet TW; Pretlow TP; Giaconia JM; Edgehouse NL; Pretlow TG; Schwartz S
Prostate; 1999 Sep; 41(1):7-11. PubMed ID: 10440870
[TBL] [Abstract][Full Text] [Related]
2. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar.
Nagabhushan M; Miller CM; Pretlow TP; Giaconia JM; Edgehouse NL; Schwartz S; Kung HJ; de Vere White RW; Gumerlock PH; Resnick MI; Amini SB; Pretlow TG
Cancer Res; 1996 Jul; 56(13):3042-6. PubMed ID: 8674060
[TBL] [Abstract][Full Text] [Related]
3. A new human prostate carcinoma cell line, 22Rv1.
Sramkoski RM; Pretlow TG; Giaconia JM; Pretlow TP; Schwartz S; Sy MS; Marengo SR; Rhim JS; Zhang D; Jacobberger JW
In Vitro Cell Dev Biol Anim; 1999; 35(7):403-9. PubMed ID: 10462204
[TBL] [Abstract][Full Text] [Related]
4. Androgen-dependent and -independent human prostate xenograft tumors as models for drug activity evaluation.
Chen CT; Gan Y; Au JL; Wientjes MG
Cancer Res; 1998 Jul; 58(13):2777-83. PubMed ID: 9661891
[TBL] [Abstract][Full Text] [Related]
5. Xenografts of primary human prostatic carcinoma.
Pretlow TG; Wolman SR; Micale MA; Pelley RJ; Kursh ED; Resnick MI; Bodner DR; Jacobberger JW; Delmoro CM; Giaconia JM
J Natl Cancer Inst; 1993 Mar; 85(5):394-8. PubMed ID: 8433392
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line.
Tepper CG; Boucher DL; Ryan PE; Ma AH; Xia L; Lee LF; Pretlow TG; Kung HJ
Cancer Res; 2002 Nov; 62(22):6606-14. PubMed ID: 12438256
[TBL] [Abstract][Full Text] [Related]
7. Metastatic phenotype in CWR22 prostate cancer xenograft following castration.
Seedhouse SJ; Affronti HC; Karasik E; Gillard BM; Azabdaftari G; Smiraglia DJ; Foster BA
Prostate; 2016 Mar; 76(4):359-68. PubMed ID: 26642837
[TBL] [Abstract][Full Text] [Related]
8. Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1.
Amler LC; Agus DB; LeDuc C; Sapinoso ML; Fox WD; Kern S; Lee D; Wang V; Leysens M; Higgins B; Martin J; Gerald W; Dracopoli N; Cordon-Cardo C; Scher HI; Hampton GM
Cancer Res; 2000 Nov; 60(21):6134-41. PubMed ID: 11085537
[TBL] [Abstract][Full Text] [Related]
9. Androgenic regulation of growth factor and growth factor receptor expression in the CWR22 model of prostatic adenocarcinoma.
Myers RB; Oelschlager D; Manne U; Coan PN; Weiss H; Grizzle WE
Int J Cancer; 1999 Jul; 82(3):424-9. PubMed ID: 10399960
[TBL] [Abstract][Full Text] [Related]
10. Stepwise genetic changes associated with progression of nontumorigenic HPV-18 immortalized human prostate cancer-derived cell line to a malignant phenotype.
Hukku B; Mally M; Cher ML; Peehl DM; Kung H; Rhim JS
Cancer Genet Cytogenet; 2000 Jul; 120(2):117-26. PubMed ID: 10942801
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic switch from paracrine to autocrine role of hepatocyte growth factor in an androgen-independent human prostatic carcinoma cell line, CWR22R.
Nakashiro K; Hara S; Shinohara Y; Oyasu M; Kawamata H; Shintani S; Hamakawa H; Oyasu R
Am J Pathol; 2004 Aug; 165(2):533-40. PubMed ID: 15277227
[TBL] [Abstract][Full Text] [Related]
12. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays.
Bubendorf L; Kolmer M; Kononen J; Koivisto P; Mousses S; Chen Y; Mahlamäki E; Schraml P; Moch H; Willi N; Elkahloun AG; Pretlow TG; Gasser TC; Mihatsch MJ; Sauter G; Kallioniemi OP
J Natl Cancer Inst; 1999 Oct; 91(20):1758-64. PubMed ID: 10528027
[TBL] [Abstract][Full Text] [Related]
13. Comparative genomic hybridization and molecular cytogenetic characterization of two prostate cancer xenografts.
Williams BJ; Jones E; Kozlowski JM; Vessella R; Brothman AR
Genes Chromosomes Cancer; 1997 Apr; 18(4):299-304. PubMed ID: 9087570
[TBL] [Abstract][Full Text] [Related]
14. CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma.
Wainstein MA; He F; Robinson D; Kung HJ; Schwartz S; Giaconia JM; Edgehouse NL; Pretlow TP; Bodner DR; Kursh ED
Cancer Res; 1994 Dec; 54(23):6049-52. PubMed ID: 7525052
[TBL] [Abstract][Full Text] [Related]
15. Altered corepressor SMRT expression and recruitment to target genes as a mechanism that change the response to androgens in prostate cancer progression.
Godoy AS; Sotomayor PC; Villagran M; Yacoub R; Montecinos VP; McNerney EM; Moser M; Foster BA; Onate SA
Biochem Biophys Res Commun; 2012 Jul; 423(3):564-70. PubMed ID: 22695118
[TBL] [Abstract][Full Text] [Related]
16. Establishing prostate cancer patient derived xenografts: lessons learned from older studies.
Russell PJ; Russell P; Rudduck C; Tse BW; Williams ED; Raghavan D
Prostate; 2015 May; 75(6):628-36. PubMed ID: 25560784
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor expression and cellular proliferation during transition from androgen-dependent to recurrent growth after castration in the CWR22 prostate cancer xenograft.
Kim D; Gregory CW; French FS; Smith GJ; Mohler JL
Am J Pathol; 2002 Jan; 160(1):219-26. PubMed ID: 11786415
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor up-regulates insulin-like growth factor binding protein-5 (IGFBP-5) expression in a human prostate cancer xenograft.
Gregory CW; Kim D; Ye P; D'Ercole AJ; Pretlow TG; Mohler JL; French FS
Endocrinology; 1999 May; 140(5):2372-81. PubMed ID: 10218991
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor regulation of G1 cyclin and cyclin-dependent kinase function in the CWR22 human prostate cancer xenograft.
Gregory CW; Johnson RT; Presnell SC; Mohler JL; French FS
J Androl; 2001; 22(4):537-48. PubMed ID: 11451350
[TBL] [Abstract][Full Text] [Related]
20. Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays.
Mousses S; Bubendorf L; Wagner U; Hostetter G; Kononen J; Cornelison R; Goldberger N; Elkahloun AG; Willi N; Koivisto P; Ferhle W; Raffeld M; Sauter G; Kallioniemi OP
Cancer Res; 2002 Mar; 62(5):1256-60. PubMed ID: 11888886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
